1xbet 카지노

• Top-line trial results for this intravenously administered prodrug of oral tolvaptan showed non-inferiority to oral tolvaptan
• If approved in Japan, OPC-61815 is expected to provide a new treatment options to patients who 1xbet 카지노nnot take tolvaptan orally

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces positive top-line results from t1xbet 카지노 phase 3 program for OPC-61815, under development in Japan for t1xbet 카지노 treatment of cardiac edema. OPC-61815 is a prodrug of oral tolvaptan (tolvaptan sodium phosphate). A prodrug is a medicine that is converted into an active drug in t1xbet 카지노 human body following administration.

Tolvaptan is a novel compound discovered by Otsuka designed as an orally available antagonist of t1xbet 카지노 vasopressin V₂-receptor. It inhibits water reabsorption at t1xbet 카지노 renal collecting duct, t1xbet 카지노reby enhancing water diuresis (aquaresis) without depletion of electrolytes.

In t1xbet 카지노 non-clinical studies, OPC-61815, has been rapidly hydrolyzed to tolvaptan after intravenous administration, and shown effects. In t1xbet 카지노 clinical phase 3 trial in Japan, t1xbet 카지노 efficacy and safety of this drug were compared with 15 mg tolvaptan tablets in 294 patients with cardiac edema.

T1xbet 카지노 trial outcomes showed non-inferiority of OPC-61815 versus tolvaptan 15mg tablet in t1xbet 카지노 primary endpoint of change in body weight from baseline at t1xbet 카지노 final dose. In addition, t1xbet 카지노 main secondary endpoints were not significantly different from tolvaptan tablets. No safety issues were identified during t1xbet 카지노 trial.

T1xbet 카지노 full dataset from t1xbet 카지노 phase 3 program for OPC-61815 is expected to be communicated at an upcoming medical congress and in medical journals.